Heart Attacks Without Blockages: SCAD, MINOCA, and Takotsubo

Heart Attacks Without Blockages: SCAD, MINOCA, and Takotsubo

---

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

---

In Brief

This article is for the woman who has had a heart attack, was told her arteries looked clean, and is uncertain what happened, whether the workup was complete, and what comes next.

Most heart attacks happen the way they are described in medical textbooks: cholesterol plaque ruptures, a clot forms, a coronary artery becomes blocked. The standard cardiac toolkit was built for that pattern and works well for it. Not every heart attack follows that pattern, and the ones that don’t are more common in women than in men. Three syndromes the standard framework historically missed or mischaracterized disproportionately affect women: spontaneous coronary artery dissection (SCAD), an acute tear in a coronary artery wall, with approximately 90 percent of cases in women; MINOCA, a confirmed heart attack without major artery blockage, about three times more common in women than in men (10.5 percent versus 3.4 percent in the ACTION Registry of 322,523 patients); and Takotsubo cardiomyopathy, sudden transient pumping dysfunction triggered by stress, with approximately 90 percent of cases in postmenopausal women. (1,2,3,4) Each requires a workup beyond the standard angiogram. Each has mechanism-specific treatments that differ from standard heart attack care. This article walks through each.

Three Syndromes at a Glance

	SCAD	MINOCA	Takotsubo
What it is	Acute tear in the wall of a coronary artery	Confirmed heart attack with no major artery blockage on angiogram	Sudden, usually transient weakening of the heart’s pumping function triggered by intense stress
Who	~90% female, often age 40–50	More common in women: 10.5% of female heart attacks vs 3.4% of male heart attacks (ACTION Registry, n=322,523)	~90% female, mostly postmenopausal (mean age 67)
Key associations	Pregnancy, fibromuscular dysplasia, connective tissue disorders	Underlying mechanism must be identified (SCAD, vasospasm, microvascular disease, embolism, etc.)	Emotional or physical stress trigger in most cases
What the angiogram shows	May appear normal or near-normal; tear can be subtle	By definition, no blockage of ≥50% in any major artery	Usually clean — no obstruction
Treatment principle	Conservative care often preferred; stenting can make the tear worse	Mechanism-specific: treatment follows the cause	Supportive; pumping function typically recovers over days to weeks

What all three share: all more common in women, all historically under-recognized, all carry meaningful short- and long-term risk. None is benign.

Why the Standard Framework Doesn’t Fit These Syndromes

The standard clinical model of an acute heart attack proceeds along a recognizable path. Cholesterol plaque builds up in a coronary artery over decades. Eventually a vulnerable plaque ruptures or erodes, and a blood clot forms at the site. The artery becomes occluded, the downstream heart muscle starts to die, and the patient presents with chest pain.

The diagnostic workup confirms acute coronary syndrome — the umbrella term for unstable angina, NSTEMI (a heart attack without complete artery blockage on the ECG), and STEMI (a heart attack with complete artery blockage on the ECG). Treatment proceeds with blood thinners, anti-platelet medications, and procedures to open the blocked artery — typically with stents.

This framework correctly explains most heart attacks in men and most heart attacks in women. It does not encompass several mechanisms that account for a meaningful share of heart attacks in women, particularly younger women.

SCAD involves no cholesterol plaque rupture. The tear in the artery wall produces a separate channel (a “false lumen”) within the wall itself, which can compress the actual blood-flow channel and starve the heart muscle of oxygen. Treatments optimized for plaque-and-clot heart attacks — high-dose anti-clotting medications, stents — can be counterproductive in SCAD, where the underlying problem is a mechanical wall tear rather than a clot. (1)

MINOCA, by definition, involves a confirmed heart attack without a major artery blockage on angiogram. The underlying mechanisms are heterogeneous and include cholesterol plaque rupture with a clot that has dissolved or shifted by the time of imaging, transient artery spasm (vasospasm), small-vessel (microvascular) dysfunction, a clot that traveled from elsewhere (embolism), spontaneous coronary artery dissection that has healed, and Takotsubo cardiomyopathy (in some classifications). Diagnosing MINOCA as a final answer without further workup misses the underlying cause. (2)

Takotsubo presents with chest pain, elevated troponin, and electrocardiogram changes that closely mimic a heart attack. The angiogram is typically clean. Imaging of the heart’s pumping function shows a characteristic ballooning pattern of the lower chamber. The mechanism appears to involve a surge of stress hormones damaging the heart muscle directly, rather than coronary artery obstruction. (4)

The historical clinical pathway — chest pain workup, troponin, angiogram, diagnosis — does not produce the right answer for any of these three syndromes without additional workup beyond what the standard pathway includes.

Spontaneous Coronary Artery Dissection (SCAD)

The 2018 American Heart Association scientific statement on SCAD, authored by Hayes and colleagues, synthesizes the contemporary understanding. (1) The 2017 Canadian SCAD Cohort Study (CanSCAD), the largest prospective study of SCAD outcomes to date, provides additional specific data. (5)

What SCAD Is

Spontaneous coronary artery dissection is the spontaneous formation of a tear or blood collection (hematoma) within the wall of a coronary artery. The tear creates a separate channel — a false lumen — within the arterial wall, which can compress the actual blood-flow channel and reduce blood flow to the heart muscle.

The tear is not caused by cholesterol plaque rupture, by a catheter or device inserted into the artery, or by a traumatic injury. It occurs in arteries that may otherwise look angiographically normal or near-normal. (1)

The angiographic appearance of SCAD ranges from obvious — with a clearly visible wall flap and false channel — to subtle and easily missed. Modern intracoronary imaging techniques (optical coherence tomography, or OCT, and intravascular ultrasound, or IVUS — small imaging devices inserted into the artery itself) can confirm SCAD when conventional angiography is unclear. (1)

Who Gets SCAD

SCAD is meaningfully more common in women than in men, with approximately 90 percent of cases occurring in women in major contemporary registries. (1,5) Women with SCAD tend to be younger than women with typical plaque-based heart attacks — frequently in their 40s and early 50s. SCAD accounts for a substantial proportion of heart attacks in women aged 50 and under, with reported estimates ranging from 8.7 percent to 35 percent depending on the study and the diagnostic intensity. (1)

Several factors are associated with SCAD.

Pregnancy and the early postpartum period. SCAD is the most common single cause of heart attack during pregnancy or in the weeks after delivery, accounting for approximately 43 percent of pregnancy-associated heart attacks. (1)

Fibromuscular dysplasia (FMD). FMD is a non-cholesterol-related vascular condition that produces narrowing, bulges, and tears in arteries throughout the body. It occurs more often in women and is identified in a substantial proportion of women with SCAD. The relationship is bidirectional — women with SCAD should be screened for FMD in other arteries (carotid, renal, others). (1)

Connective tissue disorders. Inherited conditions affecting the connective tissue framework of arteries, such as Marfan syndrome and certain types of Ehlers-Danlos syndrome (particularly the vascular subtype), increase SCAD risk. (1)

Extreme physical or emotional stress. Reported as triggers in many cases. (1,5)

Hormonal factors. The strong female predominance and the patterns around pregnancy and around menopause suggest hormonal contributions, though the exact mechanisms remain incompletely understood. (1)

Why SCAD Recognition Matters

SCAD cannot be diagnosed if it is not considered. A younger woman who presents with an acute heart attack and whose angiogram is interpreted as normal or near-normal may have a SCAD that careful re-examination of the images, or additional intracoronary imaging, would identify. Awareness of SCAD has substantially improved in the cardiology community over the past decade, but the diagnostic workflow still depends on the treating clinician considering it as a possibility.

If you or someone you love has had a heart attack at a younger age with an angiogram interpreted as showing no significant obstruction, asking whether SCAD was specifically considered — and whether intracoronary imaging was performed if the angiogram was inconclusive — is reasonable and appropriate.

MINOCA: A Working Diagnosis, Not a Final One

The 2019 American Heart Association scientific statement on MINOCA, authored by Tamis-Holland and colleagues, is the contemporary framework. (2)

What MINOCA Is

MINOCA is defined by three specific criteria: (2)

• A confirmed acute heart attack by standard biomarker and clinical criteria (the Fourth Universal Definition of Myocardial Infarction)
• Coronary angiography showing no major artery blockage (less than 50 percent narrowing in any major epicardial coronary vessel)
• No alternative non-ischemic explanation for the troponin elevation

The contemporary scientific statement emphasizes that MINOCA is a working diagnosis requiring further workup to identify the underlying mechanism. It is the starting point of the investigation, not the conclusion. (2) The mechanisms underlying MINOCA include:

• Cholesterol plaque disruption with a clot that has subsequently dissolved or moved — and so does not produce a visible obstruction at the time of imaging
• Coronary vasospasm (transient artery spasm)
• Coronary microvascular dysfunction (small-vessel disease, addressed in Article 7 of this series)
• Spontaneous coronary artery dissection (SCAD)
• Coronary embolism — a clot that has traveled from elsewhere (most commonly from atrial fibrillation or valvular disease)
• Takotsubo syndrome (in some classifications)
• Myocarditis — strictly excluded by the MINOCA definition but commonly considered in the differential

How MINOCA Is Worked Up

The standard MINOCA workup typically includes cardiac magnetic resonance imaging (cardiac MRI), which can show the pattern of a heart attack, identify myocarditis, or reveal other muscle pathology. This is often supplemented by intracoronary imaging (OCT or IVUS) if the mechanism is still unclear after the MRI, and by provocative coronary function testing in selected cases — a procedure during angiography in which specific medications are injected into the coronary arteries to test for spasm or to measure the function of the small vessels. The specific workup is individualized to each patient. (2)

Who Gets MINOCA

MINOCA is meaningfully more common in women than in men. The ACTION Registry — a large US registry of 322,523 patients with confirmed heart attacks — found MINOCA in 10.5 percent of women versus 3.4 percent of men (approximately a three-fold higher rate in women). (3) MINOCA patients tend to be younger than typical heart attack patients and have a lower burden of conventional cardiovascular risk factors.

Prognosis

MINOCA is not benign. In contemporary registries, MINOCA patients have lower in-hospital mortality than patients whose heart attack was caused by a major artery blockage, but their subsequent cardiovascular event rates are substantial and depend on the underlying mechanism. Recurrent heart attacks, heart failure, and cardiovascular death rates are not trivial. (2) The clinical implication is that the discovery of MINOCA should lead to a focused workup, not to discharge with reassurance.

Takotsubo Cardiomyopathy

The 2015 International Takotsubo Registry, published in the New England Journal of Medicine by Templin and colleagues, provides the most comprehensive contemporary characterization of this syndrome. (4)

What Takotsubo Is

Takotsubo cardiomyopathy is a sudden, usually transient dysfunction of the left ventricle (the heart’s main pumping chamber). It is characterized by acute wall motion abnormalities — most commonly a pattern in which the base of the heart contracts normally but the lower portion (apex) balloons out and fails to contract — that typically resolve over days to weeks. The presentation closely mimics a heart attack, with chest pain, troponin elevation, and electrocardiogram changes. (4)

The Japanese word takotsubo refers to a traditional pot used to catch octopus, with a narrow neck and a bulbous base. The shape of the ventricle during the syndrome resembles this pot — hence the name. The apical ballooning pattern is most common, but several variants exist (including a mid-ventricular pattern and an inverted “reverse Takotsubo” pattern).

Who Gets Takotsubo

The International Takotsubo Registry of 1,750 patients across 26 centers in Europe and the United States established the demographic and clinical pattern. (4) Approximately 90 percent of patients were women (89.8 percent), and the mean age was 66.8 years. Nearly 80 percent of all patients in the registry were women older than 50 — that is, postmenopausal women.

Triggers preceded the event in most cases. Contrary to the popular framing of Takotsubo as primarily an “emotional” condition, physical triggers were actually slightly more common than emotional triggers in the registry: physical triggers (medical illness, surgery, severe pain, asthma exacerbation) in 36.0 percent of patients, emotional triggers (bereavement, conflict, fear, anger) in 27.7 percent, both in 7.8 percent, and no identifiable trigger in 28.5 percent. (4)

What Causes Takotsubo

The exact mechanism is not fully established. The leading hypothesis involves a surge of stress hormones — catecholamines such as adrenaline and noradrenaline — damaging heart muscle directly or causing transient dysfunction. Catecholamine levels measured at presentation in Takotsubo patients are substantially higher than those in patients with typical acute coronary syndromes. The downstream mechanisms — direct catecholamine toxicity to heart muscle, microvascular dysfunction, transient coronary spasm — remain under active investigation. The strong female and postmenopausal predominance suggests an estrogen-related contribution to vulnerability.

Prognosis

The Templin registry challenged the older view of Takotsubo as a benign, self-limited condition. In-hospital mortality was 4.1 percent — comparable to the 4.5 percent mortality in age- and sex-matched patients with acute coronary syndrome of equivalent severity (P=0.59). (4) During long-term follow-up, the rate of major adverse cardiac and cerebrovascular events was 9.9 percent per patient-year, and the rate of death was 5.6 percent per patient-year. (4) Recurrent Takotsubo events occur in a meaningful minority of patients.

The label “stress cardiomyopathy” can be misleading if it suggests the condition is transient and inconsequential. Takotsubo can be fatal in its acute phase. Long-term cardiovascular event rates are not negligible. The condition warrants the same seriousness as any other major cardiac event.

How Takotsubo Is Diagnosed

The diagnostic workup typically includes coronary angiography (to exclude obstructive disease), imaging of the heart’s pumping function (most commonly echocardiography, and in some cases ventriculography), and cardiac MRI in selected cases. The diagnostic criteria require characteristic wall motion abnormalities that cannot be explained by a coronary artery obstruction, in the appropriate clinical context. (4)

Cardiac MRI is particularly useful when the presentation is ambiguous. Takotsubo, acute myocarditis, and a typical heart attack can all present with chest pain, elevated troponin, and electrocardiogram changes — and they can be difficult to distinguish on initial clinical grounds alone. Cardiac MRI can separate the three by the pattern of myocardial edema and late gadolinium enhancement, each of which has a distinctive appearance for each diagnosis. When the initial workup leaves the diagnosis uncertain, cardiac MRI often resolves it.

Treatment by Mechanism

The standard treatment toolkit for a typical heart attack — high-dose anti-platelet therapy, anti-clotting medications, and stenting through percutaneous coronary intervention (PCI) — was developed for one specific kind of heart attack: cholesterol plaque rupture with clot formation in a major coronary artery.

When the underlying mechanism is something else, the standard toolkit may not be appropriate. For each of the three syndromes in this article, treatment depends on what is actually happening in the artery and the heart muscle — not on the fact that a heart attack has occurred.

Condition	Medical management	Stenting / PCI	Surgery (CABG)
SCAD	Conservative care often preferred for stable patients (the artery often heals on its own over weeks to months); aspirin commonly continued; beta-blockers commonly recommended long-term to reduce recurrence; dual anti-platelet therapy individualized; statins selectively used; screen for fibromuscular dysplasia in other arteries	Avoid routine stenting. PCI in SCAD carries higher complication rates than in plaque-based disease — pushing a stent into a torn arterial wall can extend the dissection. Reserve for specific high-risk situations	Rare. Considered only for: left main artery dissection with ongoing ischemia, severe dissection involving two or more major proximal arteries, failed PCI, or refractory ischemia not controlled by other measures
MINOCA	Treat the underlying mechanism once identified. Plaque disruption → standard atherothrombotic regimen (aspirin, statin, beta-blocker, ACE inhibitor or ARB). Vasospasm → calcium-channel blockers (cornerstone). Embolism → anticoagulation if a source is identified. Microvascular dysfunction → as in Article 7. SCAD → as in this row. Myocarditis → reclassified as a non-MINOCA diagnosis	Only if a treatable culprit lesion or mechanism is identified. Routine stenting in MINOCA without identifying the mechanism is not appropriate	Rare. Depends entirely on the underlying mechanism
Takotsubo	Supportive care during recovery. Heart-failure-style management for those with reduced pumping function (ACE inhibitors, beta-blockers, diuretics in the absence of LVOT obstruction). Anticoagulation for patients with documented LV thrombus (approximately 5 percent of cases)	Not useful unless true obstructive coronary disease is present alongside Takotsubo	Rare. Considered only for mechanical complications (e.g., ventricular wall rupture) or severe cardiogenic shock requiring mechanical circulatory support

The principle in all three rows is the same: a confirmed heart attack does not automatically mean the standard heart attack mechanism. And the standard heart attack mechanism does not automatically mean the standard heart attack treatment. Identify the mechanism first. The treatment follows.

SCAD: Conservative Care Is Usually the Right Answer

SCAD is the clearest example of how a heart attack does not automatically translate to a stenting decision. The 2018 American Heart Association statement and subsequent registry data establish a clear framework. (1,5)

Conservative management — medical care without immediate stenting or surgery — is the contemporary default for clinically stable SCAD patients with preserved blood flow. The dissected artery often heals over weeks to months on its own. In the Canadian SCAD Cohort Study (CanSCAD), the large majority of patients were managed conservatively, with low rates of in-hospital major adverse events. (5)

Coronary stenting (PCI) is reserved for specific high-risk situations: ongoing heart attack with continuing ischemia, hemodynamic instability, sustained dangerous heart rhythms, cardiac arrest, blockage of a major proximal artery threatening a large area of heart muscle, or progression to artery occlusion after initial conservative management. (1) Even in these situations, PCI in SCAD is technically more difficult than in plaque-based disease and carries a meaningfully higher risk of complications — including extension of the dissection by the procedure itself.

Coronary artery bypass grafting (CABG, or “open heart bypass surgery”) is rare in SCAD. It is considered specifically for: (1)

• Left main coronary artery dissection with ongoing ischemia or active heart attack
• Severe dissection involving two or more major proximal arteries
• Failed PCI (technical failure, complications during the procedure, or inability to restore blood flow)
• Ongoing severe ischemia not controlled by conservative care or PCI

Long-term medical therapy in SCAD:

• Beta-blockers — commonly recommended long-term based on observational data from CanSCAD suggesting reduced risk of recurrent SCAD. (5)
• Aspirin — generally continued long-term.
• Dual anti-platelet therapy (DAPT) — the optimal antiplatelet strategy for SCAD remains uncertain. For patients managed conservatively, practice varies between aspirin alone and short-course DAPT. After stenting, the duration of DAPT is individualized based on the location of the SCAD and the number and size of stents used. The high-intensity, prolonged DAPT regimen used after plaque-based stenting is not automatically applied. (1)
• Statins — used selectively based on the individual cardiovascular risk profile, not reflexively (SCAD is not an atherosclerotic disease).
• Screening for fibromuscular dysplasia in carotid, renal, and other vascular beds is recommended at the index hospitalization or shortly after.
• Cardiac rehabilitation — observational evidence supports benefit.

Recurrent SCAD is not rare. Observational cohorts report recurrence rates in the range of approximately 10 to 30 percent over long-term follow-up, with newer prospective data suggesting lower rates than older retrospective series. This is part of why ongoing surveillance and long-term cardiovascular follow-up matter. (1,5)

Exercise after SCAD. Extreme isometric exertion and very high-intensity exercise are often approached cautiously after SCAD, while cardiac rehabilitation and a graduated return to activity are generally encouraged. Specific exercise prescriptions are individualized and developed with the cardiology team.

Pregnancy after SCAD. Pregnancy and the early postpartum period appear to carry an elevated risk of recurrent SCAD, though the absolute magnitude of that risk varies across reported cohorts and is not precisely established. For a woman who has had a SCAD and is considering another pregnancy, the decision is individualized and made jointly with cardiology and maternal-fetal medicine — and ideally at a center with specific experience managing pregnancy in SCAD survivors. The conversation typically considers the specific SCAD characteristics, residual coronary anatomy, time since the index event, presence of associated conditions like fibromuscular dysplasia, and the woman’s reproductive goals. The conclusion is not always “do not become pregnant again.” Pregnancy is sometimes appropriate, with planned multidisciplinary surveillance. The conclusion is that this is one of the most important conversations a SCAD survivor of reproductive age can have with her cardiology team, and the conversation should happen before the next pregnancy, not after it begins.

MINOCA: The Treatment Depends on What Is Causing It

MINOCA is the clearest case of why “one heart attack, one treatment” is the wrong frame. Because MINOCA is an umbrella diagnosis covering several distinct mechanisms, treatment must follow the mechanism. The 2019 American Heart Association MINOCA scientific statement explicitly establishes this principle. (2)

Plaque disruption is more common than is often recognized — reported in approximately 16 to 40 percent of MINOCA cases in intracoronary imaging studies, with one IVUS-based study finding 38 percent. Treatment follows the standard atherothrombotic disease pathway — aspirin, statin, beta-blocker, ACE inhibitor or ARB. If plaque rupture or erosion is documented on OCT or IVUS during the workup, this treatment applies regardless of the absence of a major blockage on standard angiography. (2)

Coronary vasospasm. The cornerstone is calcium-channel blockers, which directly counter the spasm tendency. Long-acting nitrates can be added, though the evidence for additional benefit beyond calcium-channel blockers is less clear. Smoking cessation is particularly important — tobacco is a known trigger of spasm.

Certain non-selective beta-blockers (such as propranolol) can paradoxically worsen vasospasm because they block the vessel-relaxing receptors while leaving the constricting receptors unopposed. For this reason, non-selective beta-blockers are generally avoided in patients with vasospastic disease. (2)

Coronary thromboembolism. Anticoagulation is the cornerstone if an embolic source is identified — most commonly atrial fibrillation, intracardiac thrombus, or paradoxical embolism through a patent foramen ovale (PFO). Duration and type of anticoagulation depend on the source. (2)

Coronary microvascular dysfunction. Addressed in Article 7 of this series — combines aggressive risk factor management with anti-anginal medications targeted at the microvasculature.

Spontaneous coronary artery dissection (SCAD). Managed as described in the SCAD treatment section above (conservative care for stable patients, PCI for specific high-risk situations, CABG reserved for the most severe cases or failed PCI).

The principle running through all of these is the same. MINOCA is not treated empirically with a one-size-fits-all approach. The mechanism is identified, then the appropriate treatment for that mechanism is applied. This is why the AHA statement emphasizes that MINOCA is a working diagnosis, not a final one.

Takotsubo: Supportive Care, with Important Caveats

Takotsubo treatment is, with the current state of the evidence, supportive rather than disease-specific. No randomized clinical trial has established a particular medication as proven to treat Takotsubo itself. Acute management focuses on managing complications and supporting the heart while the muscle dysfunction resolves on its own — which it typically does over days to weeks.

For patients without significant complications: cardiac monitoring, observation, and standard heart-failure-type medications (beta-blockers, ACE inhibitors or ARBs) commonly used during the recovery phase.

For patients with heart failure or low cardiac output: standard heart failure management — diuretics if congested, ACE inhibitors or ARBs, beta-blockers — adapted to the patient’s hemodynamic status.

For patients who develop cardiogenic shock (which occurs in approximately 10 percent of Takotsubo patients overall, with higher rates in those with biventricular involvement): the critical first step is identifying whether the patient has left ventricular outflow tract (LVOT) obstruction.

This distinction is clinically critical. In a small subset of Takotsubo patients, the heart’s pumping pattern itself creates a partial blockage right where blood exits the heart’s main pumping chamber. When this happens, the usual emergency treatment for severe heart failure — medications that make the heart pump harder (inotropes) — can actually make things worse. Bedside echocardiography quickly identifies whether LVOT obstruction is present and guides the next step.

• Without LVOT obstruction: inotropes may be used to support cardiac output.
• With LVOT obstruction: inotropes are contraindicated — they worsen the obstruction. Management involves IV fluids, beta-blockers to slow the heart and prolong filling time, and mechanical circulatory support (such as an intra-aortic balloon pump or other temporary support devices in selected cases) if needed.

The reflexive use of inotropes in shock — which is the default for most acute cardiac shock — can be actively harmful in the subset of Takotsubo patients with LVOT obstruction. Bedside echocardiography before initiating inotropes is essential.

For patients with documented LV thrombus (occurs in approximately 5 percent of Takotsubo cases): anticoagulation for at least 3 months, or until ventricular function and the thrombus have resolved.

Follow-up imaging. Repeat echocardiography is commonly performed during recovery to document normalization of ventricular function and to confirm thrombus resolution if a clot was present. Timing varies — often within days to a few weeks of the acute event, with additional imaging at 1 to 3 months — because most patients recover ventricular function within this window. Failure of the ventricle to recover normal function on follow-up imaging should prompt reconsideration of the diagnosis (Takotsubo is, by definition, a transient condition) and a search for alternative or coexisting cardiac pathology.

Takotsubo can recur, although most patients recover ventricular function after each episode. Long-term cardiovascular follow-up therefore remains important. (4)

The medications most often used during recovery — beta-blockers and ACE inhibitors — are commonly given because they are reasonable, well-tolerated, and align with how heart failure of any cause is treated. Their evidence base specifically for Takotsubo is observational, not from randomized trials. They are not formally established as disease-specific therapy.

The Psychological Weight of These Diagnoses

A heart attack at any age is a serious event. A heart attack with a clean angiogram, or one tied to extreme stress, often carries additional psychological weight that conventional cardiology follow-up does not always address.

Women who have had SCAD frequently describe persistent anxiety after the event — fear of recurrence (which is not unfounded given the recurrence data), fear of exertion, uncertainty about pregnancy and birth control decisions, and grief that something so serious happened in arteries that were not supposed to be diseased. Several patient communities exist specifically for SCAD survivors and many women describe them as among the most helpful resources during recovery.

Women who have had Takotsubo often had a precipitating event — bereavement, severe illness in self or a loved one, surgery, an acute crisis — that itself produced significant psychological impact even before the cardiac event. The cardiac event then layers on top of an already difficult moment, and the recovery period often includes processing both the trigger and the cardiac diagnosis simultaneously. The “stress cardiomyopathy” label can inadvertently suggest that the cardiac event was somehow secondary or psychosomatic, which it is not. Takotsubo is a real, sometimes fatal, cardiac event that is precipitated by a real biological cascade.

For both conditions, mental health support during recovery is reasonable for some women and essential for others. Survivor communities, formal counseling, and the time required to process what happened are all part of recovery. The cardiology follow-up alone is not always sufficient.

What Your Care Should Cover

Being told that you had a heart attack but your arteries “looked clean” can feel confusing — sometimes even dismissive. It is neither. It is the beginning of a more focused investigation, not the end of one.

The workup may extend beyond the angiogram. Cardiac MRI, intracoronary imaging, or provocative testing may be discussed in the days or weeks after the initial event. Each of these is a tool to identify the specific mechanism. Asking “do we know yet what caused this?” is reasonable and appropriate.

You may benefit from a cardiologist with specific experience. SCAD, MINOCA, and Takotsubo are not rare, but they require clinicians who recognize them — particularly SCAD, where management differs substantially from typical heart-attack care. Larger cardiology centers and academic medical centers often have cardiologists who focus on these conditions. It is reasonable to ask for a referral if you feel your current team is uncertain.

Cardiac rehabilitation is usually recommended. Even though these are not the typical plaque-and-clot heart attacks, supervised cardiac rehabilitation helps with physical recovery, exercise confidence, and the cardiovascular conditioning that supports long-term heart health. Most patients with SCAD, MINOCA, or Takotsubo can and should participate, with the specifics individualized.

Long-term follow-up matters. Each of these conditions has long-term cardiovascular implications. The general expectation is regular cardiology follow-up, with the cadence tailored to your specific diagnosis, risk profile, and how you are doing. Long-term medication, lifestyle factors, blood pressure control, and (where relevant) management of associated conditions like fibromuscular dysplasia all matter.

Family conversations may come up. SCAD has uncommon but real associations with inherited connective tissue conditions and with fibromuscular dysplasia. If a connective tissue disorder is suspected or confirmed, your cardiology team may discuss screening for first-degree relatives.

The emotional recovery is real and warrants explicit attention. Persistent anxiety, fear of recurrence, and difficulty resuming usual activities are common after each of these events. Mental health support during recovery is reasonable to seek and reasonable to ask for. The cardiology team can refer.

Article 9 of this series covers the conditions that amplify women’s cardiovascular risk — diabetes, autoimmune disease, and chronic inflammation — and why their cardiovascular effects in women differ from their effects in men.

The Bottom Line

A clean-looking angiogram in the setting of a confirmed heart attack is not the end of the workup. It is the point at which the targeted workup begins.

A confirmed heart attack (elevated troponin) combined with a coronary angiogram showing less than 50 percent blockage in all major arteries establishes a working diagnosis of MINOCA — not the final answer. The next step is to identify the underlying mechanism, which typically involves three parallel lines of inquiry. Re-examination of the angiogram for subtle SCAD, with intracoronary imaging (OCT or IVUS) if the standard angiogram is inconclusive. Cardiac MRI to look for the imaging pattern of a heart attack, myocarditis, Takotsubo cardiomyopathy, or other heart-muscle pathology. Provocative coronary function testing in selected cases, to evaluate for vasospasm or microvascular dysfunction. Once a specific mechanism is identified, the treatment follows the mechanism — not the default treatment for a typical plaque-based heart attack.

For a woman experiencing a heart attack whose angiogram shows no obstruction or only minimal disease, the relevant questions to raise with the cardiology team include the following. Has SCAD been specifically considered and ruled out, with careful re-examination of the angiogram and intracoronary imaging if needed? Has cardiac MRI been done to look for the underlying mechanism? If MINOCA is the working diagnosis, what is the plan for identifying the underlying cause? What is the appropriate treatment based on the specific mechanism rather than the default treatment for a typical plaque-based heart attack?

A heart attack without a blocked artery is still a heart attack and requires its own focused workup. The mechanism — and the right treatment — depend on which of these syndromes is responsible. None of the three is benign. None of the three is psychosomatic. None of the three should end with reassurance and discharge after a clean angiogram.

---

Next: Article 9 covers the conditions that amplify women’s cardiovascular risk — diabetes, autoimmune disease, and chronic inflammation — and why their cardiovascular effects in women differ from their effects in men.

---

Key Terms

Acute coronary syndrome (ACS): An umbrella term for the acute presentations of coronary artery disease, including unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI).

Apical ballooning syndrome: A descriptive term for the most common Takotsubo pattern, in which the apex (lower portion) of the heart’s main pumping chamber balloons out and fails to contract during the acute episode.

Catecholamines: A group of stress hormones, including epinephrine (adrenaline) and norepinephrine, that surge during acute physical or emotional stress. Thought to play a central role in triggering Takotsubo cardiomyopathy.

Coronary angiography: The standard test for examining the major heart arteries, in which dye is injected into the coronary arteries and X-ray images are taken. Excellent for detecting major artery blockages; can miss SCAD if the dissection is subtle, and does not directly visualize the small vessels.

Coronary artery bypass grafting (CABG): A heart surgery in which a healthy blood vessel (typically taken from the chest, arm, or leg) is used to create a new route for blood to flow around a blocked or diseased coronary artery. Rarely needed in the syndromes covered in this article, but considered for severe SCAD involving the left main or multiple proximal arteries, for failed PCI, or for mechanical complications of Takotsubo.

Dual antiplatelet therapy (DAPT): A combination of two medications (typically aspirin plus another antiplatelet) that reduce platelet activity and the formation of blood clots. Standard treatment after most plaque-based heart attacks and after coronary stenting.

Fibromuscular dysplasia (FMD): A non-atherosclerotic vascular disorder that produces narrowing, bulges, and tears in arteries throughout the body. Occurs more often in women and is strongly associated with SCAD.

Intracoronary imaging (OCT and IVUS): Small imaging devices inserted into the coronary arteries during angiography to produce high-resolution images of the artery wall. OCT (optical coherence tomography) uses light; IVUS (intravascular ultrasound) uses sound waves. Both can confirm SCAD and other non-obstructive pathologies that standard angiography may miss.

Left ventricular outflow tract (LVOT) obstruction: A complication in which the area where blood exits the heart’s main pumping chamber becomes functionally narrowed during contraction, reducing forward blood flow. Important to identify in Takotsubo cardiomyopathy because the treatment for shock with LVOT obstruction (IV fluids, beta-blockers, avoiding inotropes) is different from the treatment for shock without LVOT obstruction (often inotropes).

MINOCA: Myocardial infarction with non-obstructive coronary arteries. A working diagnosis for a confirmed heart attack in a patient whose coronary angiogram shows less than 50 percent narrowing of all major arteries.

Percutaneous coronary intervention (PCI): A catheter-based procedure to open blocked coronary arteries, typically with balloon angioplasty and stenting.

SCAD: Spontaneous coronary artery dissection. An acute tear within the wall of a coronary artery, producing a false channel that can compress the actual blood-flow channel.

Stress cardiomyopathy: Another name for Takotsubo cardiomyopathy.

Takotsubo cardiomyopathy: A sudden, usually transient dysfunction of the heart’s main pumping chamber, typically triggered by intense emotional or physical stress. Named for a Japanese octopus-catching pot whose shape resembles the ventricle during the acute episode.

Troponin: A protein found in heart muscle. When heart muscle is damaged (as in a heart attack), troponin is released into the blood and can be measured. The blood test for troponin is the primary biomarker for diagnosing a heart attack.

References

1. Hayes SN, Kim ESH, Saw J, et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation. 2018;137(19):e523–e557.
2. Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139(18):e891–e908.
3. Smilowitz NR, Mahajan AM, Roe MT, et al. Mortality of myocardial infarction by sex, age, and obstructive coronary artery disease status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines). Circ Cardiovasc Qual Outcomes. 2017;10(12):e003443.
4. Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373(10):929–938.
5. Saw J, Humphries K, Aymong E, et al. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol. 2017;70(9):1148–1158.